950834-06-7
950834-06-7 structure
- Name: CXL-1020
- Chemical Name: CXL-1020
- CAS Number: 950834-06-7
- Molecular Formula: C7H9NO5S2
- Molecular Weight: 251.28
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
- Create Date: 2022-09-30 05:35:50
- Modify Date: 2024-04-08 13:32:25
-
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1].
| Name | CXL-1020 |
|---|
| Description | CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1]. |
|---|---|
| Related Catalog | |
| Target |
L-type calcium channel |
| In Vivo | CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice[1]. CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure[2]. Animal Model: Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)[1] Dosage: 100 μg/kg/min Administration: For 30 min Result: Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. Animal Model: Dogs (coronary microembolization-induced heart failure)[2]3 and 10 mg/kg/min Dosage: 3 and 10 mg/kg/min Administration: 4-hour intravenous infusion Result: Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner. |
| References |
| Molecular Formula | C7H9NO5S2 |
|---|---|
| Molecular Weight | 251.28 |